News

Septodont closes acquisition of majority stake in Inibsa

Published October 29, 2024

Septodont is pleased to announce the successful completion of its acquisition of a 51% interest in Inibsa. This operation follows the receipt of customary regulatory approvals and satisfaction of closing conditions.



In this strategic transaction, Septodont has acquired a controlling stake in Inibsa, alongside Acteon, a Dentressangle portfolio company, as a strong partner and non-controlling shareholder. This acquisition represents another significant milestone in Septodont’s long term growth strategy.





Olivier SCHILLERCEO of Septodont Group

“ This acquisition of control of Inibsa will expand Septodont’s development in dental products and help us further strengthen our geographical footprint. This is an important acquisition for us that will provide compelling value creation and accelerated growth opportunities given the complementary nature of our assets and teams ”



Inibsa is a global pharmaceutical group located in Spain specializing in the production of injectable anesthetics and in the distribution of a large portfolio of dental products.

Other news you may be interested in

All news
News

March 19th, 2025

Septodont participates at IDS 2025

News

March 19th, 2025

Septodont announces new governance structure

Press release

February 11th, 2025

Septodont awarded for its project AI BOT Claire at the 2025 Data and AI Night

All news